POSTER SESSION V
Wednesday, March 11, 2009 — 9:30 AM - 12:00 Noon
Convention Center Exhibit Hall
Click on the blue numbers in parentheses to display abstracts.
Click the button next to any title to add to Itinerary Planner...
BREAST PATHOLOGY
Poster#
Title and Authors
Itinerary Planner
1
Assessment of Prognostic Value of Classical Clinical-Pathological Factors in Hormone Receptor Positive Breast Carcinoma
(286)
J Segui, E Alcaraz, L Sanchez-Tejada, C Alenda, A Paya, G Peiro, F Aranda - Universitary General Hospital, Alicante, Spain
Estrogen Receptor Status Is Generally Stable during Disease Progression from Primary to Metastatic Breast Cancer
(191)
EY Han, N Sneige, Y Gong - The University of Texas M. D. Anderson Cancer Center, Houston, TX
Does Estrogen Receptor Expression Vary with Fixation Time?
(201)
JA Ibarra, LW Rogers - MemorialCare Breast Center at OCMMC, Fountain Valley, CA; MemorialCare Breast Center at LBMMC, Long Beach, CA
Hormone Receptor Immunohistochemistry: The Prevalence of ER-PR+ Results Are PR Antibody Clone-Dependent
(178)
DC Gingell, R Bhargava, DJ Dabbs - Magee-Women's Hospital of UPMC, Pittsburgh, PA
Concordance between Semi-Quantitative Immunohistochemical Assay and OncoTypeDX™ RT-PCR Assay for Estrogen and Progesterone Receptors
(123)
R Bhargava, S Beriwal, DJ Dabbs - Magee-Womens Hospital of UPMC, Pittsburgh, PA
DNA Methylation of ESR1 and PGR in Breast Cancer: Relationship to Pathologic and Epidemiologic Features
(292)
ME Sherman, MM Gaudet, M Campan, XR Yang, JD Figueroa, J Lissowska, B Peplonska, LA Brinton, M Garcia-Closas, PW Laird - National Cancer Institute, Rockville, MD; Memorial Sloan-Kettering Cancer Center, New York, NY; University of Southern California, Los Angeles, CA; Cancer Center and M. Sklodowska-Curie Institute of Oncology, Warsaw, Poland; Nofer Institute of Occupational Medicine, Lodz, Poland
Estrogen Receptor and Androgen Receptor in Normal Human Breast Tissue and Breast Carcinoma
(323)
J Weinsensel, P Tang, D Hicks, M Berenson, A diSant'Agnese, X Wang - U of Rochester, Rochester, NY
Detection of Disseminated Tumor Cells in Bone Marrow of Patients with Breast Cancer: Comparison of Two Enrichment Techniques
(222)
S Krishnamurthy, J Reuben, M Cristofanilli, A Lucci - U.T. M. D. Anderson Cancer Center, Houston, TX
Novel Non-Biotin Polymeric Immunohistochemical Visualization Systems Improve Estrogen Receptor Evaluation in Breast Cancer
(280)
RM Rocha, K Miller, NG Moraes, J Vassallo, FA Soares, H Gobbi - University College London, London, United Kingdom; Universidade Federal de Minas Gerais, Belo Horizonte, Brazil; Universidade Estadual de Campinas, Campinas, Brazil; Universidade Estadual de Sao Paulo, Sao Paulo, Brazil
Loss of 16q in High Grade Breast Cancer Is Associated with ER Status: Evidence for Progression in Luminal Tumours?
(254)
R Natrajan, MBK Lambros, C Marchio, DSP Tan, R Vatcheva, F Geyer, KK Shiu, D Hungermann, SM Rodriguez-Pinilla, J Palacios, A Ashworth, H Buerger, JS Reis-Filho - Institute of Cancer Research, London, United Kingdom; University of Muenster, Muenster, Germany; CNIO, Madrid, Spain; Hospital Universitario Virgen del Rocio, Seville, Spain; Institute of Pathology, Paderborn, Germany
Does Estrogen Receptor Alpha Specific MicroRNAs Expression Correlate with ESR1 Transcript Levels in Breast Cancer?
(253)
M Nassiri, S Salardini, C Reyes, S Ramos, J Olczyk, M Nadji, FA Tavassoli - Indiana University School of Medicine, Indianapolis, IN; Yale University School of Medicine, New Haven, CT; University of Miami, Miami, FL
Estrogen Receptor Expression in Breast and 6F11
(155)
JL Deschenes, S Mitchell, R Linford, S Fahim, T Hiruki - Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada
ER and PR Assessment by Central IHC: Examination and Comparison of Percent Positive Cells and Nuclear Staining Intensity in ECOG Breast Cancer Study 2197
(114)
S Badve, R Gray, B Childs, T Maddala, M Liu, S Rowley, N Davidson, S Shak, LJ Goldstein, GW Sledge, JA Sparano, FL Baehner - ECOG, Indianapolis, IN; Sanofi-aventis, Bridgetown, NJ; Genomic Health, Redwood City, CA; UCSF, San Francisco, CA
The Effects of Additional Tumor Cavity Sampling at the Time of Breast Conserving Surgery on Final Margin Status, Volume of Resection, and Pathologist Work-Load
(132)
KL Chandler, J Park, M Rizzo, G Birdsong, MB Mosunjac - Emory University, Atlanta, GA
Can We Predict Which Cases of Atypical Ductal Hyperplasia on Breast Core Needle Biopsy Will Upgrade?
(106)
KH Allison, PR Eby, J Kohr, WB DeMartini, CD Lehman - University of Washington Medical Center, Seattle, WA; Seattle Cancer Care Alliance, Seattle, WA
Are Columnar Cell Alteration and Sclerosing Adenosis, Independent Risk Markers for Breast Cancer?
(251)
A Nassar, DW Visscher, CA Reynolds, RA Vierkant, SS Anderson, MH Frost, LC Hartmann - Mayo Clinic, Rochester, MN; University of Michigan, Ann Arbor, MI
Histopathological Analysis of Nipple Involvement by Breast Carcinomas in Mastectomy Specimens from a Single Institution
(319)
JL Wang, N Iqbal, JM Wang, P Ding, A Chen, P Tai, K Skinner, DG Hicks, P Tang - University of Rochester Medical Center, Rochester, NY; RTI Health Solution, Research Triangle Park, NC
Significance of Lobular Carcinoma In Situ, "Nuclear Grade 2" on Breast Core Needle Biopsies
(171)
F Gao, G Carter, M Chivukula - Magee Women's Hospital of UPMC, Pittsburgh, PA
button next to any title to add to Itinerary Planner...
Add
